about
Phase II study of sorafenib in patients with relapsed or refractory lymphoma.Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults.Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers.Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor.Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF.Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.Radioimmunotherapy and secondary leukemia: a case report.Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression.Immunization of Patients with Malignant Melanoma with Autologous CD34+ Cell-Derived Dendritic Cells Transduced Ex Vivo with a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I TrialMyeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemiaEfficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-upCD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID miceAge- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone
P50
Q33401136-8811BC57-5F4F-458D-8CEF-7B510B338E04Q33417756-17FC2004-6582-46B3-8EAD-6115D673D784Q40149288-BD3E18BD-8F43-427D-9818-51A38A1C1F24Q42535831-D2032D2C-BD65-4BDE-9C7C-C97A9FD120C2Q43490516-6A37C369-DF97-478F-8915-968DF72D0E04Q45048444-A3483637-4CCF-4007-B148-E7C74523A87EQ47262671-6A0535C1-0F8D-49CF-9613-6BDFB57867FDQ47263261-AC7F5586-7390-40C9-9A86-C59A25962236Q47763723-4FAB459A-EE35-420C-86CA-AD44BD64951FQ48333236-69A7A5F7-9B19-4737-863A-6BCF697D6276Q48336057-9367D9ED-FE12-441B-AE05-F46AC699B5A8Q50688251-A70686BA-5C6F-45CA-A68D-A791BC0CED4DQ51010848-F0C8D944-FFAA-42A3-8082-C313CDE13060Q54481816-3964D5DA-2B72-45FF-B8F5-58A5FAA412A1Q54567794-2F4FAFEC-5DDD-4A32-A790-47B428B4B5B9Q54863084-244ABDB8-A82C-48AE-A3F9-4EC0309BFA44Q57081488-63DE6B54-5743-47FC-A270-2F527CA32E82Q61774244-F5E3770A-7757-46C1-A89F-09E4B75B545FQ61774245-55C51B99-22A1-4B2F-8C85-583C24FEDACDQ63185439-CA69C83A-3951-45E4-B836-661E68179BAAQ79970294-13473A72-DA5B-4EFF-BB7E-816702340153
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Anna Guidetti
@ast
Anna Guidetti
@en
Anna Guidetti
@es
Anna Guidetti
@nl
Anna Guidetti
@sl
type
label
Anna Guidetti
@ast
Anna Guidetti
@en
Anna Guidetti
@es
Anna Guidetti
@nl
Anna Guidetti
@sl
prefLabel
Anna Guidetti
@ast
Anna Guidetti
@en
Anna Guidetti
@es
Anna Guidetti
@nl
Anna Guidetti
@sl
P106
P1153
6602113227
P21
P31
P496
0000-0002-4195-6397